《新股消息》心通医疗(02160.HK)今日起招股 入场费12,322.94元
由微创医疗(00853.HK)分拆旗下微创心通医疗科技(02160.HK)公布招股详情,计划发售2.06亿股股份,当中10%在港公开发售,招股价介乎11.1至12.2元,每手1,000股,入场费为12,322.94元。由今日(26日)至本周五(29日)中午公开招股,预计於2月4日上市。摩根大通、花旗及中金为联席保荐人。
专注於心脏瓣膜疾病领域创新的经导管及手术解决方案的研发和商业化的微创心通医疗是次引入16名基石投资者,包括源峰基金、Hillhouse Funds、GIC、雪湖资本及华夏基金等,合共认购1.25亿美元股份。
以招股价中位数11.65元计,公司预计集资净额为22.48亿元,当中30%将用於核心产品VitaFlow II;27%将用於现有产品管线的其他产品;3.4%将用於首款商业化TAVI产品VitaFlow;15%将用於通过并购、授权引进安排或股权投资与包括医疗器械企业及研究机构在内的全球赋能者合作扩展集团产品组合提供资金;14.6%将用於扩大产能并提高生产VitaFlow及VitaFlow II的能力;10%将作营运资金及一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.